Balance Sheet Account Detail

(a) Inventories

Inventories are stated at the lower of cost (determined on a first in, first out basis) or market value. Inventories consisted of the following:



	March 31, 2012		December 31, 2011
Raw materials	$	4,380	$	3,260
Work-in-process	5,052		4,617
Finished goods	10,064		10,222
Total inventories	$	19,496	$	18,099

(b) Goodwill and intangible assets

The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets, and related accumulated amortization:



	March 31, 2012			December 31, 2011
Goodwill	$	27,073		$	27,073

Intangible assets:
Indefinite lived intangibles
In-process research and development	$	40,100		$	40,100
Trademarks and trade names	2,708			2,708

Finite lived intangibles
Developed technology	$	14,050		$	14,050
Accumulated amortization	(13,816		)	(13,465		)
Developed technology, net	234			585

Patent	100			100
Accumulated amortization	(60		)	(54		)
Patent, net	40			46
Intangible assets (excluding goodwill), net	$	43,082		$	43,439

Goodwill and other intangible assets with indefinite lives are not subject to amortization, but are tested for impairment annually or whenever events or changes in circumstances indicate that the asset might be impaired. The Company most recently performed an annual update to goodwill and indefinite lived intangible assets impairment analysis as of June 30, 2011, with no resulting impairment. The Company will continue to test for impairment as of June 30 each year, or whenever events or changes in circumstances indicate that an asset might be impaired.

Intangible assets with finite lives are amortized over the expected useful life and related impairment testing is performed upon the occurrence of impairment indicators, if/when they occur.

The Company recognized amortization expense on intangible assets during the three months ended March 31, 2012 and 2011 as follows:



	Three Months Ended, March 31
	2012		2011
Amortization expense	$	356	$	351

Estimated amortization expense for the remainder of 2012 and the three succeeding fiscal years (which includes estimated amortization of in-process research and development to commence with the expected launch of the Nellix Device in Europe during the second half of 2012) is as follows:



	Amortization Expense
Remainder of 2012	$	364
2013	$	318
2014	$	483
2015 and thereafter	$	39,209